Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RSV fusion protein inhibitor JNJ-53718678

An orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity. Upon oral administration of RSV fusion protein inhibitor JNJ-53718678, this agent specifically targets and binds to F protein on the viral surface, which inhibits RSV F protein-mediated fusion with the host cell membrane and prevents viral entry. This blocks RSV replication, reduces viral load, and decreases the severity of the disease. RSV F protein, a viral surface glycoprotein, plays a key role in RSV fusion with and entry into target cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:respiratory syncytial virus fusion protein inhibitor JNJ-53718678
RSV F protein inhibitor JNJ-53718678
Code name:JNJ 53718678
JNJ-53718678
JNJ-678
JNJ-8678
JNJ53718678
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search